Why Canopy Growth (TSX:WEED) Stock Fell 17% in May

Canopy Growth Corp’s (TSX:WEED)(NYSE:CGC) potential multi-billion acquisition of New York-based Acreage Holdings has drawn a lot of criticism.

| More on:

Canopy Growth (TSX:WEED)(NYSE:WEED) lost 17% of its value in May.

There are two reasons investors fled its stock in the past month. One of them is a sector-wide problem and the other is specific to Canopy itself. Neither will likely be permanently scarring, but there could be further declines in June. Here’s why.

The first issue with investors is its announced multi-billion potential deal to buy New York-based Acreage Holdings for US$3.4 billion. Although there is a lot of support for the tie-up of the two companies, the deal will only happen if cannabis is legalized federally in the U.S. Until then, Acreage gets $300 million in a cash downpayment, and the two companies will share intelligence with each other as they continue to press Washington to move faster on legalization.

As I said, not everyone is happy about the deal. Fool contributor David Jagielski recently discussed the possibility that the deal could fall through.

Mercato Capital Management, which owns 2.7% of Acreage’s stock, believes that the company’s value, once cannabis is legalized, would be worth a lot more than the US$3.4 billion Canopy Growth is currently offering. Investors who hold Canopy Growth stock understand that CEO Bruce Linton’s arrangement is a smart way to get a foot in the door of the U.S. market without running afoul of U.S. laws and regulations.

However, if the June 19 vote fails to get enough shareholder support, Canopy Growth will be back at square one with other big players a little wiser to the company’s Trojan Horse solution. That could have consequences on the stock for some time after the vote is held.

The second thing weighing on Canopy Growth’s stock in May is the underwhelming earnings results of some cannabis producers combined with the fact that three of Canada’s largest pot producers — Aurora Cannabis, Tilray, and Cronos Group — all had good quarterly results on the top line.

Investors have no idea what Canopy Growth’s results will look like when it reports earnings June 20. Until then, WEED shares should remain in a downward trend.     

Up almost 49% in 2019, investors still ought to be happy with its year-to-date performance. 

Fool contributor Will Ashworth has no position in any stocks mentioned.  

More on Cannabis Stocks

four people hold happy emoji masks
Dividend Stocks

Wary of Mining Companies? A Lower-Risk Way to Get in on the Gold and Silver Surge

Frenco-Nevada (TSX:FNV) stock might be a wiser way to play the run in gold prices this year.

Read more »

Cannabis smoke
Cannabis Stocks

Have Cannabis Stocks Totally Gone Up in Smoke?

Let's dive into whether Canadian cannabis stocks are still investable, and what investors should make of the recent volatility in…

Read more »

Researcher works in hemp field
Cannabis Stocks

1 Undervalued Cannabis Stock to Buy and Hold Over the Next Decade

Green Thumb is a beaten-down cannabis stock that trades at a compelling valuation in September 2025.

Read more »

Researcher works in hemp field
Cannabis Stocks

Pot Stocks Rallied Hard in August: Is There More to Come?

Tilray Brands (TSX:TLRY) and the broad basket of pot stocks could heat up from here.

Read more »

Pot stocks are a riskier investment
Cannabis Stocks

Canopy Growth Stock Jumped 30% Last Month: What’s Going on?

Canopy Growth (TSX:WEED) stock is picking up traction again, making it an enticing weed play to buy on strength.

Read more »

A cannabis plant grows.
Cannabis Stocks

These Threats Facing Canopy Growth Stock Could Justify Selling it

Let's dive into whether Canopy Growth (TSX:WEED) is a top stock investors should buy right now after its recent dip…

Read more »

A person holds a small glass jar of marijuana.
Stocks for Beginners

This BioCannabis Firm Could Explode with Product Approval

This cannabis stock used to be a major name, so where does it stand now?

Read more »

Medicinal research is conducted on cannabis.
Stocks for Beginners

This TSX Health-Care Stock Is a Long-Term Buy for Patient Investors

This TSX stock continues to be one of the best long-term opportunities, if you're patient.

Read more »